Background: Most genetic variants associated with breast cancer risk have been discovered in women of European ancestry, and only a few genome-wide association studies (GWAS) have been conducted in minority groups. This research disparity persists in post-GWAS gene-environment interaction analyses. We tested the interaction between hormonal and lifestyle risk factors for breast cancer, and ten GWAS-identified SNPs among 2,107 Hispanic women with breast cancer and 2,587 unaffected controls, to gain insight into a previously reported gene by ancestry interaction in this population.
Introduction
Breast cancer is a common disease caused by genetic and nongenetic factors (e.g., hormonal and lifestyle factors) and possibly, by the interaction between the two (1) . Since the discovery of the high-penetrance breast cancer causing genes, BRCA1 and BRCA2, multiple breast cancer genome-wide association studies (GWAS) have unveiled new genetic variants with moderate to small contributions to breast cancer risk (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . When combined, all common genetic variants explain approximately 30% of familial risk (5) , and it has been postulated that an important proportion of the unexplained familial risk might be buried within complex gene-by-gene and gene-by-environment interactions (1) . Most of the risk-associated variants were originally discovered in samples that included women of European ancestry, and, to our knowledge, only four U.S.-based GWAS have been conducted in or included racial/ethnic minority groups (4, (19) (20) (21) . The gene-by-environment interaction analyses that followed the GWAS have also been mostly conducted in populations of European origin (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) . Studies assessing the relationship between intermediate to low penetrance variants and nongenetic risk factors (from here on referred to as "environmental") have had little success in identifying consistent interactions (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) . A study including over 70,000 women of European or Asian descent from 24 studies reported three statistically robust interactions: rs3817198-LSP1 and parity, rs17468277-CASP8 and alcohol consumption, and rs11249433-1p11.2 and parity (26) . A later study by the same consortium evaluated interactions for an additional set of 47 breast cancer susceptibility loci and reported nonstatistically significant interactions for three additional SNPs (rs6828523 and height; rs4808801 and number of full-term pregnancies; and rs11242675 and smoking; ref. 34) . Beyond the statistical evidence, there are no clear biologic mechanisms explaining the reported interactions.
We previously found statistically significant interactions between Indigenous American genetic ancestry and genotypes for three out of ten GWAS-discovered breast cancer risk variants in 2,107 Hispanic/Latina (from here on referred to as Hispanics) women with breast cancer and 2,587 unaffected controls (rs13387042-2q35, rs17157903-RELN, and rs7696175-TLR1; ref. 35) . For these three SNPs, the risk allele showed stronger associations among the group of women with the highest proportion of Indigenous American ancestry. The analyses were aimed at detecting heterogeneity by genetic ancestry based on the underlying hypothesis that if an interaction was observed, it could reflect either a difference in genetic predisposition between populations, or differences in environmental exposures by ancestry that would modify the associations with the genetic variants (35) .
In the present study, we investigated multiple environmental breast cancer risk factors to evaluate whether the previously observed heterogeneity by ancestry could be due to the correlation between genetic ancestry and those risk factors. First, we tested the interaction between the three GWAS-identified breast cancer risk SNPs that had previously shown interaction by ancestry (35) and 15 environmental breast cancer risk factors in a total of 4,694 Hispanic women (2,107 cases and 2,587 controls). Second, we assessed the interaction between the seven other GWAS-identified breast cancer risk SNPs and environmental risk factors to evaluate the possibility of additional interactions.
Materials and Methods
The present analysis was conducted as part of the Breast Cancer Health Disparities Study (36) . This collaborative effort to study breast cancer in Hispanic and non-Hispanic White women combined and harmonized data from two population-based casecontrol studies conducted in the United States: the 4-Corners Breast Cancer Study (4- (35, 36, (41) (42) (43) (44) (45) . All participants signed a written informed consent, and the study was approved by the Institutional Review Board for Human Subjects at each institution. The present analysis is based on 4,697 women of Hispanic/Native American origin living in the United States or Mexico with complete genotype and exposure data including 603 Hispanic cases and 730 controls from 4-CBCS, 812 Mexican cases and 989 controls from MBCS, and 692 Hispanic cases and 871 controls from SFBCS.
Genetic data
The Breast Cancer Health Disparities Study is focused on variants in genes related to inflammation, hormones, metabolism, and risk of breast cancer in Hispanic and non-Hispanic White women (36) . The genotyping platform included 10 GWAS-identified SNPs associated with breast cancer risk that were published at the time of platform design [refs. 3, 6, 11, 12, 14; rs13387042-2q35 region (G/A), rs17157903-7q22 (C/T) within the RELN gene, rs2067980-5q11 (A/G) near the MRPS30 gene, rs2180341-6q22.1-q22.33 (A/G) within the RNF146 gene, rs2981582-10q26 (C/T) within the FGFR2 gene, rs3803662-16q12.1 (C/T) within the TOX3 gene, rs3817198-11p15.5 (T/C) within the LSP1 gene, rs7696175-4p14 (C/T) near the TLR1 gene, rs889312-5q11.2 (A/C) near the MAP3k1 gene and rs999737-14q23-q24.2 (C/T) within the RAD51L1 gene]. The platform also included a set of 104 ancestry-informative markers (AIM) used to infer genetic ancestry among study participants. Details about these AIMs have been previously published (36) . All markers were genotyped using a multiplexed bead array assay based on GoldenGate chemistry (Illumina) attaining a genotyping call rate of 99%. In the present study, we analyzed the ten GWAS-identified SNPs associated with breast cancer risk in Europeans or Asians, with a focus on three variants that had previously shown statistically significant interactions with genetic ancestry in Hispanics: rs13387042-2q35, rs17157903-7q22, and rs7696175-4p14 (35) .
Environmental risk factors (reproductive/lifestyle)
From available questionnaire data that had been harmonized between the three different studies, we selected a set of breast cancer risk factors to explore whether the interaction between SNPs and genetic ancestry could be due to the correlation between environmental factors and genetic ancestry. The variables we analyzed were: menopausal status (premenopausal, postmenopausal), age at menopause (<50 or !50 years), age at menarche (<11; 11-13; !13), age at diagnosis/interview (<40; 40-50; 50-60; >60), alcohol intake (no alcohol; 10 g daily; >10 g daily), smoking status (ever, never), body mass index (<25; 25-29.9; !30 kg/m 2 ), height (below mean; above mean), waist-to-hip ratio (below mean; above mean), number of full-term pregnancies/age at first-full term pregnancy (no children; 1 or 2 children <25 years old; 1 or 2 children !25 years old; !3 children <25 years old; !3 children !25 years old), breastfeeding (no breastfeeding; 12 months; >12 months), use of hormone therapy (current, former, never), use of oral contraceptives (ever, never), and family history of breast cancer (yes, no).
Genetic ancestry estimation
Indigenous American ancestry was modeled as continuous or categorical variable depending on the analysis. The cutoffs for three ancestry categories were defined based on sample size as previously described: low Indigenous American ancestry (0%-28%), intermediate Indigenous American ancestry (29%-70%), and high Indigenous American ancestry (71%-100%; ref. 36) . We acknowledge that Hispanic populations would be best modeled as resulting from a three-way admixture process, with a European, an Indigenous American and an African component. However, the African influence in most Hispanic populations is minor (between 0% and 8%) and studies that include women of mostly Mexican or Central American origin, such as ours, do not have sufficient power to evaluate the association of this minor component with health outcomes. We focused the analyses on the Indigenous American/European proportions and estimated genetic ancestry using an unsupervised two-way admixture model. We compared the Indigenous American ancestry estimates obtained with this model, with those obtained with a supervised three-way admixture model in a subset of 1, 769 Hispanics that were included in a previous study (46) and found that the estimates were highly correlated (Pearson correlation coefficient ¼ 0.94, mean absolute difference between pairs of estimates ¼ 0.09, SD ¼ 0.06).
Statistical analysis
Indigenous American ancestry proportions were compared between the different categories of environmental risk factors by study and by case/control status using the nonparametric Kruskal-Wallis equality-of-populations rank test, which is appropriate for variables that deviate from normality, as was the case for genetic ancestry in the analyzed samples. We estimated ancestryspecific ORs for the nongenetic risk factors using logistic regression stratified by ancestry category (low, intermediate, and high Indigenous American ancestry) and adjusting for study, and tested the heterogeneity of the effects by evaluating a logistic regression model that included an environmental risk factor and genetic ancestry interaction term (ExAncestry). We also used logistic regression to evaluate SNP-by-environmental risk factor interactions (GxE), with adjustment for study, genetic ancestry and age, and to test GxE interactions stratified by ancestry, including age and study as covariates. For those stratified analyses that had results suggestive of an interaction with an environmental risk factor, we conducted likelihood ratio tests (LRT) to compare a model with the SNP-by-ancestry interaction (GxAncestry) term and adjusted for the environmental factor, to a model with GxAncestry and GxE interaction terms. In the first analyses where we tested the interaction between the three SNPs previously associated with genetic ancestry and environmental risk factors, we considered as statistically significant any interaction with a P value of <0.003, which corresponds to a Bonferroni correction for the number of risk factors tested (0.05/15). For analyses that included the other seven SNPs that did not show interaction by genetic ancestry, we took both the environmental risk factors and the number of SNPs into account when we considered statistical significance. For those analyses, we considered as statistically significant a P value of <4.8 Â 10 À4 .
Results
Many risk factors showed associations with breast cancer risk that were statistically significant at the 5% level and concordant with the direction of associations that have been previously reported for these risk factors (Table 1) . P values were higher in the low Indigenous American ancestry group, which is to be expected given that the sample size for that group was smaller than that for the other two ancestry groups. We did not find statistically significant heterogeneity by ancestry category for any of the environmental risk factors. However, among postmenopausal women, current use (vs. never use) of hormone therapy showed a positive association in all strata but a suggestive stronger association among Hispanics with high Indigenous American ancestry (P ¼ 0.05).
Environmental risk factors and Indigenous American ancestry
Average Indigenous American ancestry differed by risk factor category, and tended to be higher among women with no family history of breast cancer, women with more children at a younger age, a longer duration of breastfeeding, a higher body mass index, a higher waist-to-hip ratio, shorter height, no smoking or alcohol consumption history, no history of oral contraceptive use, with a younger age at diagnosis, menopause before age 50 years, and no history of postmenopausal hormone therapy use (Table 2 ). Despite the difference in mean Indigenous American ancestry between studies, the direction of association between ancestry and environmental risk factors is similar for most variables.
Interactions of SNPs and environmental factors by Indigenous American ancestry
Assessment of the interaction between the three SNPs that had previously shown an interaction with genetic ancestry and the environmental risk factors showed a statistically significant interaction between the SNP rs13387042-2q35 (G/A) and hormone therapy use among postmenopausal women (P interaction 0.002) and a suggestive interaction with breastfeeding among premenopausal women (P interaction 0.01; Table 3 ). We observed that the rs13387042-A variant was associated with increased breast cancer risk among postmenopausal women who had never used hormone therapy and among premenopausal women who breastfed more than 12 months. The strength of the interactions was not affected when other variables were included in the model and LRTs suggested that the models that included the rs13387042-hormone therapy or rs13387042-breastfeeding interaction terms fit the data better than the models that only included the GxAncestry interaction term (hormone therapy use: LRT P ¼ 0.021; breastfeeding: LRT P ¼ 0.028; Table 3 ). Estrogen receptor (ER) status information was available for 46% of the cases included in the present analysis. There were 720 patients with ER þ tumors and 257 patients with ER À tumors. Given that our analyses were based on stratification by ancestry and risk factors, further stratification by ER status greatly reduced the size of the groups being compared. Even though these exploratory ER status-specific results were inconclusive due to the small sample size, they suggest that the observed associations and interactions in the case/control analyses do not change for ER þ tumors (Supplementary Table S1 ).
After correcting for multiple testing, no statistically significant interactions were found for the seven SNPs that had not previously shown interactions with genetic ancestry (Supplementary  Table S2 ). For suggestive GxE interactions (P < 0.15) involving the three SNPs with previously observed GxAncestry interaction (rs13387042, rs17157903, and rs7696175), we conducted analyses stratified by genetic ancestry to evaluate whether the observed GxE interaction affected the previously observed GxAncestry interaction and found no additional statistically significant results (Supplementary Table S3 ).
Discussion
Our results suggest that the previously reported interaction between a breast cancer risk variant at 2q35 (rs13387042) and genetic ancestry in Hispanics was partially due to the correlation between genetic ancestry and two environmental breast cancer risk factors that affect estrogen levels: use of menopausal hormone therapy and breastfeeding among premenopausal women. We found that the rs13387042-derived allele (A) only increases breast cancer risk among postmenopausal women who have never been exposed to hormone therapy and among premenopausal women who have breastfed for more than 12 months.
An interaction between breast cancer susceptibility SNP rs13387042-2q35 and menopausal hormone therapy use has been previously reported (26) . Nickels and colleagues found weak evidence of interaction between the rs13387042 SNP and use of menopausal hormone therapy for combined estrogen/ progesterone formulations (P interaction ¼ 2.4 Â 10
À3
; ref. 26 ). However, they reported a stronger association among current hormone therapy users compared with never users, while we observed an association among never users only. Two other studies that investigated the interaction between previously The rs13387042 SNP is located in the short arm of chromosome 2 in an intergenic region. The derived allele A is associated with increased risk of breast cancer and is most common in African populations (77%), has lower frequencies in Europeans (51%) and Mexican Americans (41%), and is less common in Asians (12%; frequencies from 1000 Genomes Project). The closest known genes are TNP1 (transition protein 1), IGFBP5 (insulin-like growth factor binding protein 5), IGFBP2 (insulinlike growth factor binding protein 2), and TNS1 (tensin 1/matrixremodeling-associated protein 6; ref. 12). Recent studies have shown that two polymorphisms that are in strong linkage disequilibrium (LD) with rs13387042 (rs6721996 and rs4442975, r 2 ¼ 0.92) are associated with expression of the IGFBP5 gene, with decreasing expression of IGFBP5 with increasing number of A alleles (49, 50) . One of these studies was a fine-mapping effort that included functional analyses, and concluded that the rs4442975 SNP was the most likely functional variant (50) . It has been reported that IGFBP5 is expressed in breast cancer and breast cancer cell lines, and it is produced by estrogen receptor (ER)-a-positive tumors, which is concordant with the previous observation that the rs13387042 polymorphism is more strongly associated with risk of ER-positive disease (12) . IGFBP5 has been shown to inhibit cell proliferation via an insulin growth factor (IGF)-dependent mechanism (51). Adding to this, estrogeninduced transcriptional activity of ERa is reduced by IGFBP5 expression independent of IGF (51). The observation that the rs13387042 SNP is associated with breast cancer risk only among women who have never used hormone therapy is counterintuitive and needs to be further explored. A possible explanation could be that in a low estrogenic environment (such as that of postmenopausal women who do not use hormone therapy or women who breastfeed for more than a year), the level of expression of IGFBP5 becomes crucial in limiting cell growth and proliferation, while in an estrogen-rich environment, the inhibitory effect of IGFBP5 might be overridden by other estrogen-dependent regulatory mechanisms. We did not find strong evidence of heterogeneity of GxE interaction by tumor ER status, but the analysis was limited by the small size of the compared categories after ER status stratification. We were not able to explain the previously reported gene by ancestry interactions for two SNPs (rs17157903 and rs7696175) and none of the remaining polymorphisms analyzed show statistically significant GxE interactions. We cannot dismiss the possibility that our study might have failed to detect interactions between these SNPs and nongenetic risk factors due to reduced power after accounting for multiple testing. In addition, we want to acknowledge that the present analysis only included a small subset of all SNPs that have been reported to be associated with breast cancer risk to date (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) , which was determined by the limited number of published associated polymorphisms at the time of platform design. Despite these limitations, our study is the largest study to date that tested the interaction between breast cancer GWAS-identified polymorphisms and nongenetic risk factors in Hispanic women.
In summary, in this study, we present the results of a breast cancer GxE interaction analysis in Hispanic women. We found that the association between the rs13387042-2q35 polymorphism and breast cancer risk is modified by hormone therapy use among postmenopausal women and by breastfeeding among premenopausal women. The present analysis illustrates how genetic ancestry in admixed populations might not only reflect population differences in genetic predisposition, but also differences in environmental exposures that together with genetic factors can influence breast cancer risk. Future research should confirm the reported interactions as well as the negative results and properly account for the complex interactions between environment, genetics, and behavior in populations of mixed descent.
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